Pipeline-Prospector-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Company Locations

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GNOS-PV02, Pembrolizumab, INO-9012

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OX401

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Onxeo is building a strong preclinical data set for OX401, optimized for both PARP inhibition and STING response as well as bypass resistance., as homologous recombination deficiency requirements.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALT-702

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2020

            Details:

            Tumor regression and overall survival in the ALT-702 + anti-CTLA4 group was markedly better than either agent alone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SKY01

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: French Tech Seed

            Deal Size: $0.8 million Upfront Cash: Undisclosed

            Deal Type: Funding January 20, 2020

            Details:

            These funds will allow the company to accelerate the development of its flagship drug candidate, before launching a new fundraising round that will address clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NEO-STC-01

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioNTech

            Deal Size: $67.0 million Upfront Cash: $67.0 million

            Deal Type: Acquisition January 16, 2020

            Details:

            This acquisition to expand BioNTech's capabilities and strengthens its immunotherapy pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Monoclonal antibody-based therapy

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 16, 2020

            Details:

            This additional investment allows AgilVax to continue generating compelling preclinical data with their monoclonal antibody-drug conjugates targeting SLC7A11 (xCT).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GEN-001, Avelumab

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WP1244

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            The agreement grants CNS Pharmaceuticals the right to develop and commercialize WP1244, for the potential treatment of primary and metastatic brain cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BMC121

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biomica

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 13, 2020

            Details:

            This agreement will accelerate the Biomica's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoid-like molecules

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AXIM Biotechnologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 09, 2020

            Details:

            AXIM® Biotechnologies, has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech as a wholly-owned subsidiary.

            PharmaCompass